GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » PS Ratio

Celularity (Celularity) PS Ratio : 3.50 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Celularity PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Celularity's share price is $2.95. Celularity's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.84. Hence, Celularity's PS Ratio for today is 3.50.

The historical rank and industry rank for Celularity's PS Ratio or its related term are showing as below:

CELU' s PS Ratio Range Over the Past 10 Years
Min: 2.14   Med: 10.8   Max: 95.87
Current: 3.5

During the past 3 years, Celularity's highest PS Ratio was 95.87. The lowest was 2.14. And the median was 10.80.

CELU's PS Ratio is ranked better than
74.1% of 1000 companies
in the Biotechnology industry
Industry Median: 9.095 vs CELU: 3.50

Celularity's Revenue per Sharefor the three months ended in Sep. 2023 was $0.20. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.84.

Warning Sign:

Celularity Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Celularity was -38.60% per year.

Back to Basics: PS Ratio


Celularity PS Ratio Historical Data

The historical data trend for Celularity's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity PS Ratio Chart

Celularity Annual Data
Trend Dec20 Dec21 Dec22
PS Ratio
- 16.10 10.75

Celularity Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.85 10.75 6.20 5.82 2.64

Competitive Comparison of Celularity's PS Ratio

For the Biotechnology subindustry, Celularity's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celularity's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's PS Ratio distribution charts can be found below:

* The bar in red indicates where Celularity's PS Ratio falls into.



Celularity PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Celularity's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.95/0.842
=3.50

Celularity's Share Price of today is $2.95.
Celularity's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Celularity  (NAS:CELU) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Celularity PS Ratio Related Terms

Thank you for viewing the detailed overview of Celularity's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celularity (Celularity) Business Description

Traded in Other Exchanges
N/A
Address
170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
Executives
Kok Thay Lim director 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri director, officer: Chief Executive Officer 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d. director C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting 10 percent owner 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne officer: See Remarks 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher officer: General Counsel CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler director C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur director 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover director, officer: Chief Technology Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido officer: Pres, Functional Regeneration C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones director, officer: Chief Business Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932

Celularity (Celularity) Headlines

From GuruFocus